United States of America et al v. Janssen Pharmaceutical N.V. et al

  1. April 20, 2018

    Janssen Escapes Whistleblower Suit Over Off-Label Opioids

    A California federal judge Thursday nixed a False Claims Act suit accusing Johnson & Johnson subsidiary Janssen Pharmaceutical NV of using unlawful marketing practices to boost off-label sales of its opioid prescription drugs, saying a change of the pseudonym for the whistleblower who filed the suit violated the FCA's first-to-file doctrine.

  2. March 20, 2018

    Relator Assails Early Out For Janssen, J&J In Off-Label Row

    A former Janssen Pharmaceutica NV sales representative who claims the drugmaker overcharged the government, offered kickbacks and marketed drugs off-label on Monday asked a California federal judge to keep the suit alive, rebuffing the company's arguments that she lacked corroboration and forfeited her right to sue by changing her alias.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!